Magnetar Financial LLC Has $174.16 Million Holdings in C.R. Bard, Inc. (BCR)
Magnetar Financial LLC raised its holdings in C.R. Bard, Inc. (NYSE:BCR) by 11.6% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 543,407 shares of the medical instruments supplier’s stock after acquiring an additional 56,328 shares during the quarter. C.R. Bard makes up 3.9% of Magnetar Financial LLC’s holdings, making the stock its largest holding. Magnetar Financial LLC owned about 0.75% of C.R. Bard worth $174,162,000 as of its most recent SEC filing.
A number of other institutional investors have also made changes to their positions in BCR. Farallon Capital Management LLC bought a new position in C.R. Bard in the 2nd quarter valued at $463,101,000. Alpine Associates Management Inc. bought a new position in shares of C.R. Bard during the 2nd quarter worth $265,663,000. Pentwater Capital Management LP bought a new position in shares of C.R. Bard during the 2nd quarter worth $139,088,000. York Capital Management Global Advisors LLC bought a new position in shares of C.R. Bard during the 2nd quarter worth $122,678,000. Finally, CNH Partners LLC bought a new position in shares of C.R. Bard during the 2nd quarter worth $116,100,000. 79.21% of the stock is currently owned by institutional investors.
Shares of C.R. Bard, Inc. (BCR) opened at $332.49 on Wednesday. C.R. Bard, Inc. has a 12-month low of $206.71 and a 12-month high of $337.73. The firm has a market capitalization of $24,240.36, a PE ratio of 28.72, a P/E/G ratio of 2.54 and a beta of 0.52. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.37 and a current ratio of 1.72.
C.R. Bard (NYSE:BCR) last issued its quarterly earnings data on Wednesday, October 25th. The medical instruments supplier reported $3.02 earnings per share for the quarter, beating analysts’ consensus estimates of $2.96 by $0.06. C.R. Bard had a return on equity of 48.28% and a net margin of 14.75%. The company had revenue of $989.80 million for the quarter, compared to the consensus estimate of $990.64 million. During the same quarter last year, the company earned $2.64 earnings per share. The firm’s revenue for the quarter was up 5.1% compared to the same quarter last year. equities analysts expect that C.R. Bard, Inc. will post 11.89 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 29th. Investors of record on Friday, December 8th will be given a dividend of $0.26 per share. This represents a $1.04 dividend on an annualized basis and a yield of 0.31%. The ex-dividend date of this dividend is Thursday, December 7th. C.R. Bard’s payout ratio is currently 13.70%.
In related news, VP Frank Lupisella, Jr. sold 9,173 shares of the firm’s stock in a transaction dated Wednesday, October 18th. The stock was sold at an average price of $325.00, for a total transaction of $2,981,225.00. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director David M. Barrett sold 3,344 shares of the firm’s stock in a transaction dated Monday, October 30th. The shares were sold at an average price of $327.31, for a total value of $1,094,524.64. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 191,593 shares of company stock worth $62,655,513. 0.80% of the stock is owned by corporate insiders.
A number of equities analysts have recently issued reports on BCR shares. Barclays increased their price target on C.R. Bard from $245.00 to $337.00 and gave the stock an “equal weight” rating in a research report on Monday, November 6th. Jefferies Group reissued a “hold” rating and set a $317.00 price target on shares of C.R. Bard in a research report on Thursday, September 14th. Needham & Company LLC reissued a “hold” rating on shares of C.R. Bard in a research report on Thursday, October 26th. Cowen reissued a “hold” rating and set a $317.00 price target on shares of C.R. Bard in a research report on Friday, November 3rd. Finally, ValuEngine downgraded C.R. Bard from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $303.50.
TRADEMARK VIOLATION NOTICE: “Magnetar Financial LLC Has $174.16 Million Holdings in C.R. Bard, Inc. (BCR)” was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://theolympiareport.com/2017/12/06/magnetar-financial-llc-has-174-16-million-holdings-in-c-r-bard-inc-bcr.html.
C.R. Bard Company Profile
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard, Inc. (NYSE:BCR).
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.